Khurram Jamil - Aug 1, 2024 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Medical Officer
Signature
Jack W. Callicutt, by power of attorney
Stock symbol
GALT
Transactions as of
Aug 1, 2024
Transactions value $
$0
Form type
4
Date filed
8/5/2024, 08:41 AM
Next filing
Aug 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +100K $0.00 100K Aug 1, 2024 Common Stock 100K $2.50 Direct F1, F2
transaction GALT Restricted Stock Unit Award $0 +10K $0.00 10K Aug 1, 2024 Common Stock 10K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of October 31, 2024; January 31, 2025; April 30, 2025; and July 31, 2025.
F3 Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.
F4 The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.